Evolus sees FY24 revenue $260M-$266M, consensus $266.1M

Evolus (EOLS) “narrows its full year total net revenue guidance to $260 million to $266 million, representing year-over-year growth of 29% to 32% from 2023 results and well above the estimated growth rate of the aesthetic neurotoxin market. The company continues to expect its adjusted gross profit margin for the full year 2024 to be between 68% and 71%. Evolus continues to expect its full-year non-GAAP operating expenses to be between $185 million and $190 million. The company continues to expect to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025. PMA application for Evolysse(TM) Form and Evolysse(TM) Smooth injectable HA gels currently under review by the U.S. FDA with approval and launch expected by September 2025. The company projects total net revenue of at least $700 million by 2028, a compound annual growth rate of 28% from 2023, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the novel line of injectable hyaluronic acid gels beginning in 2025. Evolus continues to expect to expand operating margins by leveraging its highly synergistic, existing infrastructure, with a target of at least 20% by 2028.”